Shares in California’s Gilead Sciences (Nasdaq: GILD) fell 7% in pre-market trading on Wednesday morning, after the firm announced bad news from the US regulator on its rheumatoid arthritis (RA) candidate filgotinib.
Co-developer Galapagos (Euronext: GLPG), a Belgian company, lost a quarter of its share price after news of the Complete Response Letter (CRL) was announced.
The Food and Drug Administration has requested data from the MANTA and MANTA-RAy studies before completing its review of the submission. The agency also expressed concerns regarding the overall benefit/risk profile of the higher dose of filgotinib.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze